Identification of the proteins related to p53-mediated radioresponse in nasopharyngeal carcinoma by proteomic analysis

Journal of Proteomics

Volumn 74, Issue 12, 2011, Pages 2723-2733

  Zeng, Gu Qing ^a,b   Yi, Hong ^a   Li, Xin Hui ^a   Shi, Hui Ying ^a   Li, Cui ^a   Li, Mao Yu ^a   Zhang, Peng Fei ^a   Feng, Xue Ping ^a   Wan, Xun Xun ^a   Qu, Jia Quan ^a   Xu, Yan ^a   Sun, Yi ^a   Chen, Zhu Chu ^a   Xiao, Zhi Qiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Nasopharyngeal carcinoma; P53; Proteomics; Radiobiology; Radiotherapy

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL GROWTH ASSAY; CLONOGENIC ASSAY; CLONOGENIC SURVIVAL ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; IMAGE ANALYSIS; MASS SPECTROMETRY; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEOMICS; RADIOLOGICAL PARAMETERS; RADIORESPONSE; RADIOSENSITIVITY; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

CELL LINE, TUMOR; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; PROTEOMICS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 81055140636     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.02.012     Document Type: Article

References (37)

1. Ho J.H. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978, 4:182-198.
2. Feng X.P., Yi H., Li M.Y., Li X.H., Yi B., Zhang P.F., et al. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res 2010, 70:3450-3462.
3. Hutchinson F. Chemical changes induced in DNA by ionizing radiation. Prog Nucleic Acid Res Mol Biol 1985, 32:115-154.
4. Fei P., El-Deiry W.S. P53 and radiation responses. Oncogene 2003, 22:5774-5783.
5. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
6. Gudkov A.V., Komarova E.A. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003, 3:117-129.
7. Friend S. p53: a glimpse at the puppet behind the shadow play. Science 1994 Jul 15, 265:334-335.
8. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
9. Concin N., Stimpfl M., Zeillinger C., Wolff U., Hefler L., Sedlak J., et al. Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines. Int J Oncol 2003, 22:51-57.
10. Bristow R.G., Benchimol S., Hill R.P. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 1996, 40:197-223.
11. Chen X., Shen B., Xia L., Khaletzkiy A., Chu D., Wong J.Y., et al. Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res 2002, 62:1213-1221.
12. Pan J.J., Zhang S.W., Chen C.B., Xiao S.W., Sun Y., Liu C.Q., et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 2009, 27:799-804.
13. Herzog K.H., Chong M.J., Kapsetaki M., Morgan J.I., McKinnon P.J. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 1998, 280(5366):1089-1091.
14. Komarova E.A., Chernov M.V., Franks R., Wang K., Armin G., Zelnick C.R., et al. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 1997, 16:1391-1400.
15. King T.C., Estalilla O.C., Safran H. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. Semin Radiat Oncol 1999, 9:4-11.
16. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991, 253:49-53.
17. Spruck C.H., Tsai Y.C., Huang D.P., Yang A.S., Rideout W.M., Gonzalez-Zulueta M., et al. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 1992, 52(17):4787-4790.
18. Sun Y., Yi H., Zhang P.F., Li M.Y., Li C., Li F., et al. Identification of differential proteins in nasopharyngeal carcinoma cells with p53 silence by proteome analysis. FEBS Lett 2007, 581(1):131-139.
19. Chen Y., Ouyang G.L., Yi H., Li M.Y., Zhang P.F., Li C., et al. Identification of RKIP as an invasion suppressor protein in nasopharyngeal carcinoma by proteomic analysis. J Proteome Res 2008, 7:5254-5262.
20. Hu Z., Mellor J., Wu J., Yamada T., Holloway D., Delisi C. VisANT: data-integrating visual framework for biological networks and modules. Nucleic Acids Res 2005, 33:W352-W357.
21. Laronga C., Yang H.Y., Neal C., Lee M.H. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 2000, 275:23106-23112.
22. Yang H.Y., Wen Y.Y., Chen C.H., Lozano G., Lee M.H. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol 2003, 23:7096-7107.
23. Liu Y., Liu H., Han B., Zhang J.T. Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 2006, 66:3248-3255.
24. Black D., Solomon E. The search for the familial breast/ovarian cancer gene. Trends Genet 1993, 9:22-26.
25. Wang S., Nath N., Adlam M., Chellappan S. Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene 1999, 18:3501-3510.
26. Wang S., Zhang B., Faller D.V. Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J 2002, 21:3019-3028.
27. Fusaro G., Dasgupta P., Rastogi S., Joshi B., Chellappan S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 2003, 278:853-861.
28. Gerke V., Moss S.E. Annexins: from structure to function. Physiol Rev 2002, 82:331-371.
29. Xin W., Rhodes D.R., Ingold C., et al. Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol 2003, 162:255-261.
30. Huang Y., Jin Y., Yan C.H., Yu Y., Bai J., Chen F., et al. Involvement of Annexin A2 in p53 induced apoptosis in lung cancer. Mol Cell Biochem 2008, 309(1-2):117-123.
31. Lecona E., Barrasa J.I., Olmo N., Llorente B., Turnay J., Lizarbe M.A., et al. Upregulation of Annexin A1 Expression by Butyrate in Human Colon Adenocarcinoma Cells: Role of p53, NF-Y, and p38 Mitogen-Activated Protein Kinase. Mol Cell Biol 2008, 28:4665-4674.
32. Marutani M., Tonoki H., Tada M., Takahashi M., Kashiwazaki H., Hida Y., et al. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res 1999, 59:4765-4769.
33. Lee A.S. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 2001, 26:504-510.
34. Hendershot L.M. The ER function BiP is a master regulator of ER function. Mt Sinai J Med 2004, 71:289-297.
35. Dong D., Dubeau L., Bading J., et al. Spontaneous and controllable activation of suicide gene expression driven by the stress-inducible grp78 promoter resulting in eradication of sizable human tumors. Hum Gene Ther 2004, 15:553-561.
36. Lee E., Nichols P., Spicer D., Groshen S., Yu M.C., Lee A.S. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 2006, 66:7849-7853.
37. Zhai L., Kita K., Wano C., Wu Y., Sugaya S., Suzuki N. Decreased cell survival and DNA repair capacity after UVC irradiation in association with down-regulation of GRP78/BiP in human RSa cells. Exp Cell Res 2005, 305:244-252.